{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T00:21:14Z","timestamp":1786839674894,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.pharma.2013.05.001","type":"journal-article","created":{"date-parts":[[2013,6,14]],"date-time":"2013-06-14T00:02:51Z","timestamp":1371168171000},"page":"216-224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Extravasation des m\u00e9dicaments radiopharmaceutiques\u00a0: mesures pr\u00e9ventives et prise en charge recommand\u00e9es par la SoFRa (Soci\u00e9t\u00e9 fran\u00e7aise de radiopharmacie)"],"prefix":"10.1016","volume":"71","author":[{"given":"E.","family":"Barr\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-L.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fournel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Hosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Vercellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Rizzo-Padoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2013.05.001_bib0005","unstructured":"EONS - Directives 2007\u00a0relatives \u00e0 l\u2019extravasation. Guide de mise en application. European Oncology Nursing Society. Disponible sur\u00a0: http:\/\/www.cancernurse.eu\/documents\/EONSClinicalGuidelinesSection6-fr.pdf"},{"key":"10.1016\/j.pharma.2013.05.001_bib0010","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ejon.2003.10.003","article-title":"Extravasation","volume":"8","author":"Jones","year":"2004","journal-title":"Eur J Oncol Nurs"},{"issue":"1","key":"10.1016\/j.pharma.2013.05.001_bib0015","first-page":"57","article-title":"Vesicant extravasation: myths and realities","volume":"22","author":"McCaffrey Boyle","year":"1995","journal-title":"Oncol Nurs Forum"},{"key":"10.1016\/j.pharma.2013.05.001_bib0020","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1093\/annonc\/mdh214","article-title":"Extravasation of systemic hemato-oncological therapies","volume":"15","author":"Ener","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pharma.2013.05.001_bib0155","series-title":"Guide pratique\u00a0\u2013\u00a0Radionucl\u00e9ides et radioprotection\u00a0\u2013\u00a0Soci\u00e9t\u00e9 fran\u00e7aise de radioprotection","author":"Delacroix","year":"2004"},{"key":"10.1016\/j.pharma.2013.05.001_bib0030","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/01.rlu.0000082677.96653.22","article-title":"Potential false-positive FDG PET imaging caused by subcutaneous radiotracer infiltration","volume":"28","author":"Chiang","year":"2003","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.pharma.2013.05.001_bib0035","doi-asserted-by":"crossref","first-page":"109","DOI":"10.5603\/NMR.2011.00025","article-title":"A false-positive finding in therapeutic evaluation: hypermetabolic axillary lymph node in a lymphoma patient following FDG extravasation","volume":"14","author":"Wagner","year":"2011","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"10.1016\/j.pharma.2013.05.001_bib0040","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/RLU.0b013e318266cbdb","article-title":"FDG injection site extravasation: potential pitfall of misinterpretation and missing metastases","volume":"37","author":"Sonoda","year":"2012","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.pharma.2013.05.001_bib0045","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0001-2998(96)80002-X","article-title":"Radiopharmaceutical-related pitfalls and artifacts","volume":"26","author":"Hung","year":"1996","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.pharma.2013.05.001_bib0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2214\/ajr.177.1.1770003","article-title":"Skin injuries from fluoroscopically guided procedures: part 1, characteristics of radiation injury","volume":"177","author":"Koenig","year":"2001","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.pharma.2013.05.001_bib0055","first-page":"160","article-title":"Soins aux br\u00fbl\u00e9s apr\u00e8s un accident nucl\u00e9aire","volume":"23","author":"Bargues","year":"2010","journal-title":"Ann Burns Fire Disasters"},{"key":"10.1016\/j.pharma.2013.05.001_bib0060","first-page":"892","article-title":"Radiation injury from interstitial injection of iodine-131-iodocholesterol","volume":"32","author":"Breen","year":"1991","journal-title":"J Nucl Med"},{"key":"10.1016\/j.pharma.2013.05.001_bib0065","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/1757-1626-2-141","article-title":"Technetium and blood extravasation before gammagraphy: a case report","volume":"2","author":"Vano-Galvan","year":"2009","journal-title":"Cases J"},{"key":"10.1016\/j.pharma.2013.05.001_bib0070","first-page":"101","article-title":"Extravazation of therapeutic yttrium-90-ibritumomab tiuxetan (zevalin): a case report","volume":"21","author":"Williams","year":"2006","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.pharma.2013.05.001_bib0075","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1188\/08.CJON.275-278","article-title":"Extravasation of yttrium-90\u00a0ibritumomab tiuxetan: a case study","volume":"12","author":"Siebeneck","year":"2008","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.pharma.2013.05.001_bib0080","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.2967\/jnumed.110.083725","article-title":"Extravasation of a therapeutic dose of 131I-metaiodobenzylguanidine: prevention, dosimetry, and mitigation","volume":"52","author":"Bonta","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1016\/j.pharma.2013.05.001_bib0085","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/00003072-200307000-00026","article-title":"Lymphatic Tc-99m DMSA localization after partial-dose extravasation","volume":"28","author":"Stauss","year":"2003","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.pharma.2013.05.001_bib0090","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1053\/j.semnuclmed.2010.02.004","article-title":"Altered biodistribution of radiopharmaceuticals: role of radiochemical\/pharmaceutical purity, physiological, and pharmacologic factors","volume":"40","author":"Vallabhajosula","year":"2010","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.pharma.2013.05.001_bib0095","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00004424-199401000-00010","article-title":"Dosimetric consequences of radiopharmaceutical infiltrations","volume":"29","author":"Castronovo","year":"1994","journal-title":"Invest Radiol"},{"key":"10.1016\/j.pharma.2013.05.001_bib0100","first-page":"890","article-title":"The infiltrated radiopharmaceutical injection: risk considerations","volume":"32","author":"Hoop","year":"1991","journal-title":"J Nucl Med"},{"key":"10.1016\/j.pharma.2013.05.001_bib0105","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2967\/jnmt.110.077354","article-title":"Detection of 90Y extravasation by bremsstrahlung imaging for patients undergoing 90Y-ibritumomab tiuxetan therapy","volume":"38","author":"Rhymer","year":"2010","journal-title":"J Nucl Med Technol"},{"key":"10.1016\/j.pharma.2013.05.001_bib0110","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/BF00620478","article-title":"Dosimetric consequences of interstitial extravasation following i.v. administration of a radiopharmaceutical","volume":"12","author":"Shapiro","year":"1987","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.pharma.2013.05.001_bib0115","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/annonc\/mdi148","article-title":"Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma","volume":"16","author":"Hagenbeek","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pharma.2013.05.001_bib0120","first-page":"305","article-title":"Iatrogenic extravasations of cytotoxic or hyperosmolar aqueous solutions. Value of surgical emergency by aspiration and lavage","volume":"42","author":"Lambert","year":"1997","journal-title":"Ann Chir Plast Esthet"},{"key":"10.1016\/j.pharma.2013.05.001_bib0125","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/00015458.2000.12098514","article-title":"Early surgical suction and washout for treatment of cytotoxic drug extravasations","volume":"100","author":"Vandeweyer","year":"2000","journal-title":"Acta Chir Belg"},{"key":"10.1016\/j.pharma.2013.05.001_bib0130","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/00000637-200206000-00011","article-title":"Reducing the morbidity from extravasation injuries","volume":"48","author":"Khan","year":"2002","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.pharma.2013.05.001_bib0135","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/annonc\/mdh271","article-title":"Early subcutaneous wash-out in acute extravasations","volume":"15","author":"Giunta","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pharma.2013.05.001_bib0140","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/jso.20248","article-title":"Surgical treatment of extravasation injuries","volume":"91","author":"Napoli","year":"2005","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.pharma.2013.05.001_bib0145","unstructured":"Haute Autorit\u00e9 de sant\u00e9\u00a0\u2013\u00a0Annonce d\u2019un dommage associ\u00e9 aux soins\u00a0\u2013\u00a0Guide destin\u00e9 aux professionnels de sant\u00e9 exer\u00e7ant en \u00e9tablissement de sant\u00e9 ou en ville\u2013Mars 2011. Available from: http:\/\/www.has-sante.fr\/portail\/jcms\/c_953138\/annonce-d-un-dommage-associe-aux-soins."},{"key":"10.1016\/j.pharma.2013.05.001_bib0150","unstructured":"Autorit\u00e9 de s\u00fbret\u00e9 nucl\u00e9aire\u00a0\u2013 Guide no\u00a011\u00a0\u2013\u00a0Modalit\u00e9s de d\u00e9claration et codification des crit\u00e8res relatifs aux \u00e9v\u00e8nements significatifs dans le domaine de la radioprotection hors installation nucl\u00e9aire de base et transports de mati\u00e8res radioactives. Indice 1, version du 07\u00a0octobre 2009."}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450913000692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450913000692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:30:47Z","timestamp":1757719847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450913000692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0003450913000692"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2013.05.001","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extravasation des m\u00e9dicaments radiopharmaceutiques\u00a0: mesures pr\u00e9ventives et prise en charge recommand\u00e9es par la SoFRa (Soci\u00e9t\u00e9 fran\u00e7aise de radiopharmacie)","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2013.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}